Top 40 Best-Selling Oncology Drugs in 2023 by 2022 Data
XTalks
FEBRUARY 5, 2024
It represents the inaugural targeted therapy designed to impede the DNA damage response (DDR) in cells or tumors exhibiting a deficiency in homologous recombination repair (HRR), notably those with mutations in BRCA1 and/or BRCA2 or those where deficiency is induced by other agents, such as DNA-damaging chemotherapies.
Let's personalize your content